ADVERTISEMENT
ADVERTISEMENT

New Alzheimer's Drug Signals A Coming Increase In Research

Sidebar: For Further Information A mere two drugs currently are available for people who suffer from Alzheimer's disease, and the second, Aricept, was approved only recently. Observers call Aricept a clear improvement over the first medication, Cognex, and are optimistic that it will spur more research into Alzheimer's treatments, opening up more job opportunities for scientists studying the catastrophic brain disease. But they caution against high hopes, as there still is no way to stop its pr

Thomas Durso

Sidebar: For Further Information

A mere two drugs currently are available for people who suffer from Alzheimer's disease, and the second, Aricept, was approved only recently. Observers call Aricept a clear improvement over the first medication, Cognex, and are optimistic that it will spur more research into Alzheimer's treatments, opening up more job opportunities for scientists studying the catastrophic brain disease. But they caution against high hopes, as there still is no way to stop its progression.


NEW & IMPROVED: Aricept, only the second FDA-approved Alzheimer's drug, has fewer side effects than its predecessor.
Aricept was developed by the Eisai Co. of Japan and is being sold in the United States by Pfizer Inc. of New York under a joint agreement. Its approval from the Food and Drug Administration came in late November.

Both Aricept and Cognex--which is made by Parke-Davis, a division of Morris Plains, N.J.-based Warner Lambert...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT